| Code | Description | Claims | Beneficiaries | Total Paid |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,175 |
4,682 |
$2.96M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
7,383 |
6,833 |
$1.88M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,924 |
4,707 |
$351K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,390 |
2,165 |
$128K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
4,632 |
4,176 |
$78K |
| 80053 |
Comprehensive metabolic panel |
6,156 |
5,642 |
$52K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
895 |
837 |
$46K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
6,990 |
6,314 |
$43K |
| 80050 |
General health panel |
877 |
809 |
$38K |
| 71045 |
Radiologic examination, chest; single view |
1,870 |
1,753 |
$37K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
268 |
228 |
$27K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
367 |
356 |
$20K |
| 84484 |
|
2,112 |
1,361 |
$18K |
| 80179 |
|
868 |
798 |
$16K |
| 82077 |
|
871 |
752 |
$15K |
| 80143 |
|
754 |
687 |
$13K |
| 70450 |
Computed tomography, head or brain; without contrast material |
235 |
214 |
$12K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,620 |
1,542 |
$11K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
75 |
70 |
$11K |
| 76801 |
|
72 |
64 |
$10K |
| 81001 |
|
3,876 |
3,650 |
$8K |
| 84703 |
|
1,113 |
1,058 |
$8K |
| 83690 |
|
987 |
919 |
$6K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
555 |
530 |
$5K |
| 86850 |
|
209 |
186 |
$5K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
45 |
39 |
$4K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
252 |
121 |
$4K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
382 |
364 |
$4K |
| G0378 |
Hospital observation service, per hour |
23 |
12 |
$3K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
619 |
567 |
$3K |
| J1756 |
Injection, iron sucrose, 1 mg |
46 |
12 |
$3K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,296 |
1,185 |
$3K |
| 71046 |
Radiologic examination, chest; 2 views |
75 |
73 |
$3K |
| 87081 |
|
398 |
376 |
$2K |
| 59025 |
Fetal non-stress test |
43 |
39 |
$2K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,663 |
1,535 |
$2K |
| 84702 |
|
191 |
179 |
$2K |
| 83605 |
|
256 |
225 |
$2K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
949 |
822 |
$2K |
| 81003 |
|
1,339 |
1,243 |
$2K |
| 85610 |
|
707 |
649 |
$2K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
35 |
34 |
$1K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
54 |
29 |
$1K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
615 |
565 |
$990.51 |
| 81025 |
|
110 |
106 |
$889.11 |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
14 |
14 |
$786.19 |
| 84112 |
|
12 |
12 |
$780.10 |
| 86900 |
|
249 |
224 |
$748.33 |
| 86901 |
|
249 |
224 |
$739.58 |
| 80320 |
|
54 |
49 |
$629.89 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
633 |
577 |
$595.88 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,368 |
1,202 |
$592.49 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
71 |
65 |
$558.61 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
120 |
111 |
$542.32 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
173 |
144 |
$526.97 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
211 |
201 |
$503.18 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
17 |
14 |
$317.81 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
291 |
244 |
$311.76 |
| 87040 |
|
52 |
26 |
$300.68 |
| 36415 |
Collection of venous blood by venipuncture |
10,519 |
9,077 |
$194.06 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
59 |
53 |
$146.92 |
| 80076 |
|
27 |
25 |
$135.48 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
85 |
63 |
$77.04 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
59 |
58 |
$51.33 |
| 87186 |
|
15 |
14 |
$46.70 |
| 84443 |
Thyroid stimulating hormone (TSH) |
13 |
13 |
$43.31 |
| 82947 |
|
41 |
25 |
$35.16 |
| 85027 |
|
15 |
13 |
$27.52 |
| J2060 |
Injection, lorazepam, 2 mg |
13 |
12 |
$14.11 |
| 85730 |
|
15 |
15 |
$13.69 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
13 |
13 |
$0.00 |
| A9270 |
Non-covered item or service |
815 |
381 |
$0.00 |
| 82962 |
|
207 |
114 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
39 |
37 |
$0.00 |